Cyclic variations of bone resorption mediators and markers in the different phases of the menstrual cycle (Q51265236)

2 April 2018

title

Cyclic variations of bone resorption mediators and markers in the different phases of the menstrual cycle (English)

1 reference

2 April 2018

1 reference

Bruno Mozzanega

1

1 reference

2 April 2018

Salvatore Gizzo

2

1 reference

2 April 2018

Daniela Bernardi

3

1 reference

2 April 2018

Luigi Salmaso

4

1 reference

2 April 2018

Tito Silvio Patrelli

5

1 reference

2 April 2018

Roberto Mioni

6

1 reference

2 April 2018

Livio Finos

7

1 reference

2 April 2018

Giovanni Battista Nardelli

8

1 reference

2 April 2018

publication date

12 March 2013

1 reference

2 April 2018

Journal of Bone and Mineral Metabolism

published in

1 reference

2 April 2018

volume

31

1 reference

2 April 2018

issue

4

1 reference

2 April 2018

page(s)

461-467

1 reference

2 April 2018

Changes in bone resorption during the menstrual cycle

cites work

1 reference

https://api.crossref.org/works/10.1007/S00774-013-0430-4

Physiologic fluctuations of serum estradiol levels influence biochemical markers of bone resorption in young women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00774-013-0430-4

Effects of the natural and artificial menstrual cycle on the production of osteoprotegerin and the bone resorptive cytokines IL-1beta and IL-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00774-013-0430-4

Direct and indirect estrogen actions on osteoblasts and osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00774-013-0430-4

Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00774-013-0430-4

Minireview: the OPG/RANKL/RANK system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00774-013-0430-4

Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00774-013-0430-4

The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00774-013-0430-4

Current Recommendations for Laboratory Testing and Use of Bone Turnover Markers in Management of Osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00774-013-0430-4

Estrogen receptor isoform-specific induction of progesterone receptors in human osteoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00774-013-0430-4

Isopropanolic extract of black cohosh stimulates osteoprotegerin production by human osteoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00774-013-0430-4

The effect of exercise and estrogen on osteoprotegerin in premenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00774-013-0430-4

The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00774-013-0430-4

Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00774-013-0430-4

Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00774-013-0430-4

Tumor necrosis factor-alpha and -beta upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00774-013-0430-4

Biology of the basic multicellular unit and the pathophysiology of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00774-013-0430-4

Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00774-013-0430-4

17beta-Estradiol inhibits osteoprotegerin production by the estrogen receptor-alpha-positive human breast cancer cell line MCF-7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00774-013-0430-4

The relationship between serum levels of estradiol and osteoprotegerin in patients with anorexia nervosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00774-013-0430-4

Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00774-013-0430-4

Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00774-013-0430-4

Transforming growth factor-beta1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells

21 January 2018

1 reference

12 December 2020

Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI

1 reference

12 December 2020

Clinical review 114: hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases.

1 reference

12 December 2020

Changes in biochemical markers of osteoblastic activity during the menstrual cycle

1 reference

12 December 2020

Cervical mucus status can be accurately estimated by transvaginal ultrasound during fertility evaluation

1 reference

12 December 2020

[Osteoclastogenesis Inhibitory Factor (OCIF) /Osteoprotegerin (OPG) as a new therapeutic agent for osteoporosis]

1 reference

12 December 2020

Effects of estrogen-progestin therapy on serum levels of RANKL, osteoprotegerin, osteocalcin, leptin, and ghrelin in postmenopausal women

1 reference

12 December 2020

Cytokines in bone diseases. Cytokine and postmenopausal osteoporosis

1 reference

12 December 2020

Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women

1 reference

12 December 2020

The OPG/RANKL/RANK system in metabolic bone diseases.

1 reference

12 December 2020

Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75

1 reference

12 December 2020

Sex steroids and the construction and conservation of the adult skeleton

1 reference

12 December 2020

Postmenopausal osteoporosis: etiology, current diagnostic strategies, and nonprescription interventions

1 reference

12 December 2020

Serum Soluble Interleukin-6 Receptor and Biochemical Markers of Bone Metabolism Show Significant Variations During the Menstrual Cycle

1 reference

12 December 2020

Hormones and osteoporosis update. Estrogen and bone remodeling

1 reference

12 December 2020

10.1007/S00774-013-0430-4

Identifiers

DOI

1 reference

2 April 2018

1 reference

2 April 2018